RECEIVED CENTRAL FAX CENTER

NOV. 2.2005 10:41AM AVENTIS US PAT DEPT TO: US CENTRALIZED USPTO

ر پ (میر)

NO. 9517 P. 1/9

NOV 0 2 2005

PTO/SB/21 (09-04) Approved for use through 07/31/2006, OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no person	U.S. i as are required to respond to a co	Patent and Tr	redemerk ormation i	Office; L	J.S. DEPARTMENT OF COMMERCE
	Application Number	10/634,9		40 K- 33 II	DISDLAYS & VAIN OMB CONTIST MUNICE.
TRANSMITTAL	Filing Date	August	05, 200	3	
FORM	First Named Inventor	Hartmut	STRO	BEL et	al.
	Art Unit	1626			
(to be used for all correspondence after initial filing)	Examiner Name	POWER	S. Fior	 \a	
	Attorney Docket Number	DEAV20			J.D
Total Number of Pages in This Submission 5		DEAVE	02000	0001	
ENC	LOSURES (Check all	that apply)		
Fee Attached Amendment/Repty After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence A Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CC			Appea of App Appea (Appea Proprie Status Other below)	Il Communication to Board eals and Interferences I Communication to TC I Notice, Brief, Reply Brief) etary Information Letter Enclosure(s) (please Identify: :
Reply to Missing Parts under 37 CFR 1.52 or 1.53	OF APPLICANT, ATTO	RNEY, O	R AGI	ENT	
Firm Name AVENTIS PHARMACEUTICAL	_S INC.				
Signature		•			
Printed name Jiang Lin		1		·	
Date November 02, 2005	F	Reg. No.	51,06	5	
CERTIFIC I hereby certify that this correspondence is being facsi sufficient postage as first class mail in an envelope ad the date shown below. (USPTO FAX NO. <u>571-273-</u>	idressed to: Commissioner foi	O or deposi Patents, P	ited with	1450, /	
Signature	/				
Typed or printed name Paul Irvine				Date	November 02, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain of retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burder, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED CENTRAL FAX CENTER

NO. 9517 P. 2/5

NOV 0 2 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of STROBEL, et al.

Examiner: Powers, Fiona

Art Unit: 1626

Application No.: 10/634,979

Filed: August 5, 2003

Title: ACYLAMINO-SUBSTITUTED HETEROAROMATIC

COMPOUNDS AND THEIR USE AS PHARMACEUTICALS

Certificate of Transmission I hereby certify that this correspondence being facsimile transmitted to the USPTO, on the date indicated below.

Date of Deposit November 2, 2005

Printed Name of Person Signing Certificate Paul Irvine

Signanue

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. 18-1982 in the amount of \$180.00. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

Respectfully submitted,

Jiang Lin, Reg. No. 51,065

Agent for Applicant

Aventis Pharmaceuticals Inc. (a member of the sanofi-aventis group) U.S. Patent Operations Route #202-206 / P.O. Box 6800 Bridgewater, New Jersey 08807-0800 Telephone (908) 231-3582 Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0056 US NP

AVENTIS US PAT DEPT

NO. 9517

NOV **0 2** 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of STROBEL, et al.

Examiner: Powers, Fiona

Application No.: 10/634,979

Art Unit: 1626

Filed: August 5, 2003

TELEFAX CERTIFICATE

Title: ACYLAMINO-SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE AS PHARMACEUTICALS ! I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22213, on

November 2, 2005

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandría, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

18634979

11/03/2005 MBINAS

00000006 181982

\boxtimes	(b)	Thi	s Information Disclosure Statement is filed after the period set forth in 37 C.F.R.
		1.97	7(b), but is believed to be filed before the mailing date of a final action under §1.113
		or a	notice of allowance under §1.311, whichever occurs first.
		(1)	The undersigned attorney certifies that each item of information contained in this
			Information Disclosure Statement was cited in a communication from a foreign
			patent office in a counterpart foreign application not more than three months prior
			to the filing of this statement;
		(2)	The undersigned attorney certifies that no item of information contained in this
			Information Disclosure Statement was cited in a communication from a foreign
•			patent office in a counterpart foreign application or, to the knowledge of the
			undersigned attorney after making reasonable inquiry, was known to any
			individual designated in §1.56(c) more than three months prior to the filing of this
			statement; or
	\boxtimes	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in
			which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is
			authorized.

Respectfully submitted,

Jiang Lin, Reg. No. 51,065

Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3582
Telefax (908) 231-2626
Aventis Docket No. DEAV2002/0056 US NP

	s sign (+) inside this work Reduction Act	L	persons are required to re	App Palent and Tradem Spond to a collection of Informatic	PTO/SB/08A (10-98) roved for use through 10/31/99. OMB 0551-0031 ark Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.			
	ituls for form 1449A/			Complete if Known				
INF	ORMATIO	N DIG	CLOSURE	Application Number	10/634,979			
				Filing Date	08-05-2003			
51,	ALEMENT	BYA	PPLICANT	First Named Inventor STROBEL Group Art Unit 1626				
	(1100 pp man)	. L						
	(use as many s	eneets as	necessary)	Examiner Name	POWERS, Fiona			
Sheet	11	of	1	Attorney Docket Number	DEAV2002/0056 - US - NP			

U.S. PATENT DOCUMENTS							
Examiner nlttats*	Cite No.1	U.S. Patent C Number	Kind Code ³ (# known)	Name of Patentee or Applicant of Cited Document	/ Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		20030055093		STROBEL	03-20-2003	FADINS Appear	
		20040092513		STROBEL	05-13-2004		
		20040082628		STROBEL	29-04-2004		
		20040225013		STROBEL	11-11-2004		
		20050101599	\bot	ZEIHER	05-12-2005		
		6,759,412		STROBEL	07-06-2004		
		6,949,556		STROBEL	09-27-2005		
		6,617,359		STROBEL	09-09-2003		
		6,812,259		STROBEL	11-02-2004		
		20050054729		STROBEL	03-20-2003		
·							
			-			· · · · · · · · · · · · · · · · · · ·	
							
			∤∤				
- 	$\overline{}$		╼╂━┥	V	 		
	\Box				 	· · · · · · · · · · · · · · · · · · ·	
	f						

				FORE	IGN PATENT DOCUMEN	TS		
Examiner Cité Initials No.	Δa ₄		oreign Patent Do			Date of Publication of	Pages, Columns, Lines,	т.
	No.3	Office ³	Number ⁴	Kind Cade ⁴ (if known)	Name of Patentée or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	
		┝				<u> </u>	<u> </u>	
					· · · · · · · · · · · · · · · · · · ·			Т
			-					十
		<u> </u>						十
\longrightarrow								十
								1
								十
								1
							<u> </u>	十
								十

Examir			 		Date			
Signatu	ıre				Considered	i		
-CMANUALES	. I-M-1	 	 	 				

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ¹ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the indMdual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.